Cyclerion Therapeutics (CYCN) Institutional Ownership $2.56 -0.09 (-3.21%) Closing price 08/1/2025 03:49 PM EasternExtended Trading$2.64 +0.08 (+3.12%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclerion Therapeutics (NASDAQ:CYCN)CurrentInstitutional OwnershipPercentage75.62%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$34.17KNumber ofInstitutional Sellers(last 12 months)0 Get CYCN Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclerion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCN Institutional Buying and Selling by Quarter Cyclerion Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2025Renaissance Technologies LLC10,611$34K0.0%N/A0.392% 2/14/2024Tyndall Capital Partners L P164,429$551K100.0%+11.3%6.711% 11/14/2023Tyndall Capital Partners L P147,712$505K100.0%N/A6.129% 8/11/2023Artal Group S.A.138,955$572K0.0%-95.0%5.766% 5/9/2022Trustcore Financial Services LLC292,645$325K0.0%+47.7%0.674% 2/14/2022Diametric Capital LP100,480$173K0.1%+43.9%0.232% 2/10/2022Acadian Asset Management LLC249,792$428K0.0%N/A0.577% 11/16/2021Two Sigma Advisers LP647,700$1.99M0.0%+98.4%1.495% 11/16/2021Two Sigma Investments LP390,596$1.20M0.0%+154.1%0.902% 11/15/2021Pura Vida Investments LLC422,311$1.30M0.0%-16.8%0.975% Get the Latest News and Ratings for CYCN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2021Eversept Partners LP371,955$1.14M0.1%N/A0.859% 11/15/2021Franklin Resources Inc.116,035$356K0.0%N/A0.268% 11/12/2021Jump Financial LLC52,000$160K0.0%N/A0.120% 11/12/2021Geode Capital Management LLC490,660$1.51M0.0%+27.5%1.134% 9/17/2021Virtu Financial LLC80,384$313K0.0%-9.2%0.186% 9/3/2021Parametric Portfolio Associates LLC12,596$49K0.0%-52.0%0.029% 8/25/2021Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/18/2021Ikarian Capital LLC509,924$1.99M0.2%+70.0%1.178% 8/17/2021Millennium Management LLC389,041$1.52M0.0%N/A0.899% 8/17/2021Boothbay Fund Management LLC66,977$261K0.0%+96.3%0.155% 8/16/2021Cubist Systematic Strategies LLC17,084$67K0.0%N/A0.039% 8/16/2021Diametric Capital LP80,336$313K0.2%N/A0.186% 8/16/2021Slate Path Capital LP7,157,601$27.92M1.6%+15.5%16.539% 8/16/2021Charles Schwab Investment Management Inc.129,628$506K0.0%-35.1%0.300% 8/16/2021State Street Corp83,321$325K0.0%-79.2%0.193% 8/16/2021Tibra Equities Europe Ltd85,000$332K0.1%N/A0.196% 8/16/2021Goldman Sachs Group Inc.36,317$141K0.0%-9.4%0.084% 8/16/2021Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/13/2021Renaissance Technologies LLC284,744$1.11M0.0%+22.1%0.658% 8/13/2021Northern Trust Corp64,616$252K0.0%-73.0%0.149% 8/13/2021Geode Capital Management LLC384,820$1.50M0.0%-21.0%0.889% 8/13/2021Vanguard Group Inc.1,423,532$5.55M0.0%-14.7%3.289% 8/13/2021FMR LLC2,674,811$10.43M0.0%-1.9%6.181% 8/12/2021 Prime Capital Investment Advisors LLC22,250$87K0.0%N/A0.051% 8/12/2021XTX Topco Ltd17,968$70K0.0%+34.4%0.042% 8/12/2021Dimensional Fund Advisors LP158,994$620K0.0%+160.1%0.367% 8/12/2021JPMorgan Chase & Co.59,786$233K0.0%-43.7%0.138% 8/12/2021Ergoteles LLC96,100$375K0.0%N/A0.222% 8/11/2021Bank of New York Mellon Corp66,792$260K0.0%-31.9%0.154% 8/11/2021Deutsche Bank AG65,900$257K0.0%-18.7%0.152% This Crypto Is Set to Explode in January (Ad)Free summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…Reserve your free spot now.8/11/2021Susquehanna Fundamental Investments LLC105,572$412K0.0%N/A0.244% 5/19/2021Virtu Financial LLC88,551$247K0.0%N/A0.259% 5/18/2021D. E. Shaw & Co. Inc.68,472$191K0.0%-62.2%0.201% (Data available from 1/1/2016 forward) CYCN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCN shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclerion Therapeutics shares: Artal Group S.A. ($572K), and Tyndall Capital Partners L P ($551K), Renaissance Technologies LLC ($34K).Learn more on Cyclerion Therapeutics' institutional investors. What percentage of Cyclerion Therapeutics' stock is owned by institutional investors? 75.62% of Cyclerion Therapeutics' stock is owned by institutional investors. Learn more on CYCN's institutional investor holdings. Which institutional investors have been buying Cyclerion Therapeutics' stock? The following institutional investors have purchased Cyclerion Therapeutics' stock in the last 24 months: Tyndall Capital Partners L P ($164.43K), and Renaissance Technologies LLC ($10.61K). How much institutional buying is happening at Cyclerion Therapeutics? Institutional investors have bought a total of 10,611 shares in the last 24 months. This purchase volume represents approximately $34.17K in transactions. Related Companies ELYM Institutional Ownership AADI Institutional Ownership ATHE Institutional Ownership PEPG Institutional Ownership MRSN Institutional Ownership MURA Institutional Ownership LTRN Institutional Ownership ACRV Institutional Ownership MDCX Institutional Ownership CALC Institutional Ownership This page (NASDAQ:CYCN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
